Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview.
Acute myelogenous leukemia (AML) with chromosomal translocation (6;9)(p23;q34) is a rare disease with poor prognosis and distinct clinical and morphologic features. t(6;9) results in a chimeric fusion gene between DEK (6p23) and CAN/NUP214 (9q34). FLT3-ITD mutation is one of the most frequent mutations in AML and correlates with poor clinical outcome. Prevalence of FLT3-ITD is as high as 70% among patients with t(6;9) AML, and patients with t(6;9) AML and FLT3-ITD mutations usually have higher white blood cell counts, higher bone marrow blasts, and significantly lower rates of complete remission. t(6;9) is most commonly associated with AML-FAB-M2 and is considered by some researchers to be a separate disease entity because of its distinct clinical and morphologic features and poor prognostic implication. Distinct morphologic features of this entity include marrow basophilia and myelodysplasia, and immunophenotypically, the blast cells are positive for CD9, CD13, CD33, and HLA-DR; are usually positive for CD45 and CD38; and may be positive for CD15, CD34, and terminal deoxynucleotidyl transferase.
Chi
Yiqing
Y
Departments of Pathology, University of Illinois, Chicago, USA.
Lindgren
Valerie
V
Quigley
Sean
S
Gaitonde
Sujata
S
D001491:Basophils / Q000473:pathology*; D001853:Bone Marrow / Q000473:pathology*; D002896:Chromosomes, Human, Pair 6; D002899:Chromosomes, Human, Pair 9; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D011379:Prognosis; D014178:Translocation, Genetic